{
    "nct_id": "NCT06648473",
    "official_title": "Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib",
    "inclusion_criteria": "1. Written informed consent prior to beginning specific protocol procedures\n2. Scheduled for contrast-enhanced magnetic resonance imaging (MRI) as part of clinical care\n3. Histologically IDH1 mutant low-grade glioma (WHO grade 2) and actively receiving ivosidenib\n4. Active patient treatment or evaluations at the Preston Robert Tisch Brain Tumor Center at Duke\n5. Age ≥18 years and ≤70 years\n6. Karnofsky performance index ≥70%\n7. Primary treating physician approval\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "1. Inability to have MRIs",
    "miscellaneous_criteria": ""
}